Date: 2017-02-08
Type of information: Nomination
Compound: vice president and chief development officer
Company: Genmab (Denmark)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 8, 2017, Genmab announced the appointment of Judith Klimovsky, as executive vice president and chief development officer (CDO). Dr. Klimovsky will lead the company's global product development activities and will join the Executive team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell. Dr. Klimovsky will join Genmab on February 13, 2017 and will be based at the company's Princeton, United States location, whilst travelling regularly to the company's locations in Copenhagen, Denmark and Utrecht, The Netherlands. This appointment reflects Genmab's decision to strengthen both the leadership structure and global organization as the company develops into a strong, sustainably profitable international biotechnology company.
- Dr. Klimovsky will be responsible for Genmab's product development strategy in line with the company's corporate strategy and the 2025 Vision. Dr. Klimovsky has had a distinguished career in drug development, most recently serving as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis. She is a hematologist by training with extensive experience in various roles at BMS, Merck and Novartis, as well as having experience in hematology clinical practice. Dr. Klimovsky has broad expertise in Phase I-IV drug development and in medical affairs. She has strong leadership skills and has been instrumental in the development of several key cancer drugs.
Financial terms:
Latest news:
Is general: Yes
